Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract.
Identifieur interne : 001D34 ( PubMed/Curation ); précédent : 001D33; suivant : 001D35Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract.
Auteurs : Wen-Yu Chuang [Taïwan] ; Yu-Sun Chang ; Chi-Ju Yeh ; Yi-Chin Wu ; Chuen HsuehSource :
- Histology and histopathology [ 1699-5848 ] ; 2013.
Descripteurs français
- KwdFr :
- Agrégation plaquettaire (), Animaux, Anticorps monoclonaux (pharmacologie), Carcinome épidermoïde (métabolisme), Carcinome épidermoïde (secondaire), Glycoprotéines membranaires (immunologie), Glycoprotéines membranaires (métabolisme), Glycoprotéines membranaires (pharmacologie), Métastase lymphatique, Noeuds lymphatiques (anatomopathologie), Noeuds lymphatiques (métabolisme), Pronostic, Souris, Souris nude, Thérapie moléculaire ciblée, Tumeurs de l'oesophage (anatomopathologie), Tumeurs de l'oesophage (métabolisme), Tumeurs de la tête et du cou (anatomopathologie), Tumeurs de la tête et du cou (métabolisme), Tumeurs expérimentales (traitement médicamenteux), Tumeurs primitives multiples.
- MESH :
- anatomopathologie : Noeuds lymphatiques, Tumeurs de l'oesophage, Tumeurs de la tête et du cou.
- immunologie : Glycoprotéines membranaires.
- métabolisme : Carcinome épidermoïde, Glycoprotéines membranaires, Noeuds lymphatiques, Tumeurs de l'oesophage, Tumeurs de la tête et du cou.
- pharmacologie : Anticorps monoclonaux, Glycoprotéines membranaires.
- secondaire : Carcinome épidermoïde.
- traitement médicamenteux : Tumeurs expérimentales.
- Agrégation plaquettaire, Animaux, Métastase lymphatique, Pronostic, Souris, Souris nude, Thérapie moléculaire ciblée, Tumeurs primitives multiples.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (pharmacology), Carcinoma, Squamous Cell (metabolism), Carcinoma, Squamous Cell (secondary), Esophageal Neoplasms (metabolism), Esophageal Neoplasms (pathology), Head and Neck Neoplasms (metabolism), Head and Neck Neoplasms (pathology), Lymph Nodes (metabolism), Lymph Nodes (pathology), Lymphatic Metastasis, Membrane Glycoproteins (immunology), Membrane Glycoproteins (metabolism), Membrane Glycoproteins (pharmacology), Mice, Mice, Nude, Molecular Targeted Therapy, Neoplasms, Experimental (drug therapy), Neoplasms, Multiple Primary, Platelet Aggregation (drug effects), Prognosis.
- MESH :
- chemical , immunology : Membrane Glycoproteins.
- chemical , metabolism : Membrane Glycoproteins.
- chemical , pharmacology : Antibodies, Monoclonal, Membrane Glycoproteins.
- drug effects : Platelet Aggregation.
- drug therapy : Neoplasms, Experimental.
- metabolism : Carcinoma, Squamous Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lymph Nodes.
- pathology : Esophageal Neoplasms, Head and Neck Neoplasms, Lymph Nodes.
- secondary : Carcinoma, Squamous Cell.
- Animals, Lymphatic Metastasis, Mice, Mice, Nude, Molecular Targeted Therapy, Neoplasms, Multiple Primary, Prognosis.
Abstract
Podoplanin, a type-1 transmembrane glycoprotein, was originally named due to its expression in renal podocytes of rats. It was subsequently detected in a variety of normal human tissues, including lymphatic endothelium. Although podoplanin has been identified as the endogenous ligand of C-type lectin-like receptor 2 (CLEC-2) on platelets, its physiological functions and pathways remain largely unknown. A role in lymphangiogenesis has been suggested, since podoplanin-deficient mice were found to die at birth with a phenotype of dilated, malfunctioning lymphatic vessels and lymphedema. Podoplanin is invariably expressed in some tumors, such as lymphangioma, seminoma and follicular dendritic cell tumor, but tumor cell expression of podoplanin is highly variable in squamous cell carcinoma (SCC). It has been found that high podoplanin expression is associated with lymph node metastasis and poor prognosis in SCC of the upper aerodigestive tract. Now there is growing evidence that podoplanin is also involved in carcinogenesis, cell motility, tumor invasiveness, platelet aggregation and hematogenous metastasis. Additionally, animal studies confirmed some in vivo effects of podoplanin-overexpressing tumors, including formation of more tumor lymphatic vessels, larger lymph node metastases, more platelet aggregation, and more pulmonary metastases. Several recently developed anti-podoplanin antibodies, such as NZ-1, P2-0 and hP2-0, have been shown to attenuate podoplanin-induced platelet aggregation and prevent experimental hematogenous metastasis in nude mice. These antibodies may be applied in preclinical and clinical studies to evaluate the possibility of podoplanin-targeted therapy.
DOI: 10.14670/HH-28.293
PubMed: 23348382
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D34
Links to Exploration step
pubmed:23348382Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract.</title><author><name sortKey="Chuang, Wen Yu" sort="Chuang, Wen Yu" uniqKey="Chuang W" first="Wen-Yu" last="Chuang">Wen-Yu Chuang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan</wicri:regionArea></affiliation></author><author><name sortKey="Chang, Yu Sun" sort="Chang, Yu Sun" uniqKey="Chang Y" first="Yu-Sun" last="Chang">Yu-Sun Chang</name></author><author><name sortKey="Yeh, Chi Ju" sort="Yeh, Chi Ju" uniqKey="Yeh C" first="Chi-Ju" last="Yeh">Chi-Ju Yeh</name></author><author><name sortKey="Wu, Yi Chin" sort="Wu, Yi Chin" uniqKey="Wu Y" first="Yi-Chin" last="Wu">Yi-Chin Wu</name></author><author><name sortKey="Hsueh, Chuen" sort="Hsueh, Chuen" uniqKey="Hsueh C" first="Chuen" last="Hsueh">Chuen Hsueh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23348382</idno><idno type="pmid">23348382</idno><idno type="doi">10.14670/HH-28.293</idno><idno type="wicri:Area/PubMed/Corpus">001D34</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D34</idno><idno type="wicri:Area/PubMed/Curation">001D34</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract.</title><author><name sortKey="Chuang, Wen Yu" sort="Chuang, Wen Yu" uniqKey="Chuang W" first="Wen-Yu" last="Chuang">Wen-Yu Chuang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan</wicri:regionArea></affiliation></author><author><name sortKey="Chang, Yu Sun" sort="Chang, Yu Sun" uniqKey="Chang Y" first="Yu-Sun" last="Chang">Yu-Sun Chang</name></author><author><name sortKey="Yeh, Chi Ju" sort="Yeh, Chi Ju" uniqKey="Yeh C" first="Chi-Ju" last="Yeh">Chi-Ju Yeh</name></author><author><name sortKey="Wu, Yi Chin" sort="Wu, Yi Chin" uniqKey="Wu Y" first="Yi-Chin" last="Wu">Yi-Chin Wu</name></author><author><name sortKey="Hsueh, Chuen" sort="Hsueh, Chuen" uniqKey="Hsueh C" first="Chuen" last="Hsueh">Chuen Hsueh</name></author></analytic><series><title level="j">Histology and histopathology</title><idno type="eISSN">1699-5848</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Carcinoma, Squamous Cell (metabolism)</term><term>Carcinoma, Squamous Cell (secondary)</term><term>Esophageal Neoplasms (metabolism)</term><term>Esophageal Neoplasms (pathology)</term><term>Head and Neck Neoplasms (metabolism)</term><term>Head and Neck Neoplasms (pathology)</term><term>Lymph Nodes (metabolism)</term><term>Lymph Nodes (pathology)</term><term>Lymphatic Metastasis</term><term>Membrane Glycoproteins (immunology)</term><term>Membrane Glycoproteins (metabolism)</term><term>Membrane Glycoproteins (pharmacology)</term><term>Mice</term><term>Mice, Nude</term><term>Molecular Targeted Therapy</term><term>Neoplasms, Experimental (drug therapy)</term><term>Neoplasms, Multiple Primary</term><term>Platelet Aggregation (drug effects)</term><term>Prognosis</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agrégation plaquettaire ()</term><term>Animaux</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Carcinome épidermoïde (métabolisme)</term><term>Carcinome épidermoïde (secondaire)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Glycoprotéines membranaires (pharmacologie)</term><term>Métastase lymphatique</term><term>Noeuds lymphatiques (anatomopathologie)</term><term>Noeuds lymphatiques (métabolisme)</term><term>Pronostic</term><term>Souris</term><term>Souris nude</term><term>Thérapie moléculaire ciblée</term><term>Tumeurs de l'oesophage (anatomopathologie)</term><term>Tumeurs de l'oesophage (métabolisme)</term><term>Tumeurs de la tête et du cou (anatomopathologie)</term><term>Tumeurs de la tête et du cou (métabolisme)</term><term>Tumeurs expérimentales (traitement médicamenteux)</term><term>Tumeurs primitives multiples</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Noeuds lymphatiques</term><term>Tumeurs de l'oesophage</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Platelet Aggregation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms, Experimental</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Esophageal Neoplasms</term><term>Head and Neck Neoplasms</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Glycoprotéines membranaires</term><term>Noeuds lymphatiques</term><term>Tumeurs de l'oesophage</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Esophageal Neoplasms</term><term>Head and Neck Neoplasms</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Glycoprotéines membranaires</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Carcinome épidermoïde</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Squamous Cell</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs expérimentales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Lymphatic Metastasis</term><term>Mice</term><term>Mice, Nude</term><term>Molecular Targeted Therapy</term><term>Neoplasms, Multiple Primary</term><term>Prognosis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Agrégation plaquettaire</term><term>Animaux</term><term>Métastase lymphatique</term><term>Pronostic</term><term>Souris</term><term>Souris nude</term><term>Thérapie moléculaire ciblée</term><term>Tumeurs primitives multiples</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Podoplanin, a type-1 transmembrane glycoprotein, was originally named due to its expression in renal podocytes of rats. It was subsequently detected in a variety of normal human tissues, including lymphatic endothelium. Although podoplanin has been identified as the endogenous ligand of C-type lectin-like receptor 2 (CLEC-2) on platelets, its physiological functions and pathways remain largely unknown. A role in lymphangiogenesis has been suggested, since podoplanin-deficient mice were found to die at birth with a phenotype of dilated, malfunctioning lymphatic vessels and lymphedema. Podoplanin is invariably expressed in some tumors, such as lymphangioma, seminoma and follicular dendritic cell tumor, but tumor cell expression of podoplanin is highly variable in squamous cell carcinoma (SCC). It has been found that high podoplanin expression is associated with lymph node metastasis and poor prognosis in SCC of the upper aerodigestive tract. Now there is growing evidence that podoplanin is also involved in carcinogenesis, cell motility, tumor invasiveness, platelet aggregation and hematogenous metastasis. Additionally, animal studies confirmed some in vivo effects of podoplanin-overexpressing tumors, including formation of more tumor lymphatic vessels, larger lymph node metastases, more platelet aggregation, and more pulmonary metastases. Several recently developed anti-podoplanin antibodies, such as NZ-1, P2-0 and hP2-0, have been shown to attenuate podoplanin-induced platelet aggregation and prevent experimental hematogenous metastasis in nude mice. These antibodies may be applied in preclinical and clinical studies to evaluate the possibility of podoplanin-targeted therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23348382</PMID><DateCreated><Year>2013</Year><Month>01</Month><Day>25</Day></DateCreated><DateCompleted><Year>2013</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1699-5848</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>03</Month></PubDate></JournalIssue><Title>Histology and histopathology</Title><ISOAbbreviation>Histol. Histopathol.</ISOAbbreviation></Journal><ArticleTitle>Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract.</ArticleTitle><Pagination><MedlinePgn>293-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14670/HH-28.293</ELocationID><Abstract><AbstractText>Podoplanin, a type-1 transmembrane glycoprotein, was originally named due to its expression in renal podocytes of rats. It was subsequently detected in a variety of normal human tissues, including lymphatic endothelium. Although podoplanin has been identified as the endogenous ligand of C-type lectin-like receptor 2 (CLEC-2) on platelets, its physiological functions and pathways remain largely unknown. A role in lymphangiogenesis has been suggested, since podoplanin-deficient mice were found to die at birth with a phenotype of dilated, malfunctioning lymphatic vessels and lymphedema. Podoplanin is invariably expressed in some tumors, such as lymphangioma, seminoma and follicular dendritic cell tumor, but tumor cell expression of podoplanin is highly variable in squamous cell carcinoma (SCC). It has been found that high podoplanin expression is associated with lymph node metastasis and poor prognosis in SCC of the upper aerodigestive tract. Now there is growing evidence that podoplanin is also involved in carcinogenesis, cell motility, tumor invasiveness, platelet aggregation and hematogenous metastasis. Additionally, animal studies confirmed some in vivo effects of podoplanin-overexpressing tumors, including formation of more tumor lymphatic vessels, larger lymph node metastases, more platelet aggregation, and more pulmonary metastases. Several recently developed anti-podoplanin antibodies, such as NZ-1, P2-0 and hP2-0, have been shown to attenuate podoplanin-induced platelet aggregation and prevent experimental hematogenous metastasis in nude mice. These antibodies may be applied in preclinical and clinical studies to evaluate the possibility of podoplanin-targeted therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Wen-Yu</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yu-Sun</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Chi-Ju</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Chin</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Hsueh</LastName><ForeName>Chuen</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Histol Histopathol</MedlineTA><NlmUniqueID>8609357</NlmUniqueID><ISSNLinking>0213-3911</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117468">PDPN protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009378" MajorTopicYN="N">Neoplasms, Multiple Primary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010974" MajorTopicYN="N">Platelet Aggregation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23348382</ArticleId><ArticleId IdType="doi">10.14670/HH-28.293</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001D34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23348382
|texte= Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23348382" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |